Liquidia surges as United Therapeutics settlement removes key litigation risk

Liquidia (LQDA) will pay United Therapeutics (UTHR) $380.7M by 2027, including an initial $175M payment. LQDA reported Q3 Yutrepia sales of $222.7M and $396.1M in cash. Management expects to cover costs with existing cash and sales. LQDA stock rose 40%, with bullish retail sentiment on Stocktwits.

Liquidia (LQDA) settled with United Therapeutics (UTHR), allowing Yutrepia to remain on the market. LQDA stock surged after the agreement, which includes not appealing a patent infringement ruling. Both companies' drugs treat a form of high blood pressure.

Bank of America raised its price target for Liquidia from $38 to $42. The adjustment follows a settlement with United Therapeutics, which removed a significant litigation risk for Liquidia, causing its stock to surge.

Needham reduced Liquidia's (LQDA) price target to $58 from $72, maintaining a Buy rating after a $380.7M settlement with United Therapeutics. LQDA reported Q3 2026 Yutrepia sales of $222.7M, exceeding estimates, with a 92.5% gross margin. Analysts have mixed views on LQDA's outlook due to legal and operational challenges.

LifeSci Capital upgraded Liquidia (LQDA) to Outperform with a $59 price target, citing a recent settlement with United Therapeutics that resolved all outstanding lawsuits. LQDA is trading at $26.81, which is 90.6% below its GF Value™ of $285.95, indicating potential undervaluation. The company's GF Score™ is 69, reflecting strong growth but weak profitability and valuation. Insiders have sold $230.5 million in shares over the past year, while two gurus hold positions in LQDA.

Liquidia (LQDA) stock surged 40% after announcing a $380.7M settlement with United Therapeutics (UTHR), resolving legal disputes. Liquidia will pay UTHR $320.4M and $60.3M to settle other litigation. YUTREPIA sales continue, with Q3 net sales at $222.7M. Analysts revised price targets, with LQDA now averaging $64.43.